Using rivaroxaban in a patients with non-valvular atrial fibrillation can reduce rates of stroke and major bleeding, according to the result of the XANTUS study.
Using rivaroxaban (Xarelto) in a patients with non-valvular atrial fibrillation (NVAF) can reduce rates of stroke and major bleeding, according to the result of the XANTUS study.
XANTUS is the first large, international, prospective study describing the use of rivaroxaban for stroke prevention in a broad NVAF patient population. The study results were published in European Heart Journal.
The single-arm, observational study evaluated the safety and effectiveness of rivaroxaban for stroke prevention. The researchers studied 6784 patients with NVAF across Europe and Canada in routine clinical practice. Patients were followed up for 1 year or until 30 days after premature discontinuation.
A majority of patients (96%) did not experience major bleeding, all-cause death, or stroke/systemic embolism. Stroke occurred in 0.7% of patients per year, fatal bleeding in 0.2% per year, and critical organ bleeding in 0.7% per year. Treatment and dosing was decided by the treating physician and 5336 patients received 20 mg od, 1410 received 15 mg od, and 35 received another dose.
“The findings reaffirm the positive benefit-risk profile of rivaroxaban established in the phase III clinical trial ROCKET AF, in which rivaroxaban was shown to provide effective stroke prevention with a similar overall bleeding profile and significantly lower rates of the most feared intracranial and fatal bleeds compared with vitamin K antagonists,” XANTUS principal investigator A. John Camm, MD, professor of clinical cardiology in the Cardiovascular and Cell Sciences Research Institute at St George’s University of London, UK, said in a statement.
According to the study, major bleeding, all-cause death, and thromboembolic events occurred at higher incidence rates for the 15 mg od dose compared with the 20 mg od dose.
At the end of the study, the researchers found that 5096 (75%) of patients reported to their physicians that they were “very satisfied” or “satisfied” with their treatment. Premature discontinuation only occurred among 7.9% of patients with the main reason being an adverse event.
“These real-world insights from XANTUS complement and expand on what we already know from clinical trials, and provide physicians with reassurance to prescribe rivaroxaban as an effective and well-tolerated treatment option for the broad range of patients with AF seen in their everyday clinical practice,” said Dr Camm.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More